{"analyses":[{"ciLowerLimit":"-0.004","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.002","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.001","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.51","paramType":"Slope","paramValue":"-0.001","statisticalComment":"The treatment effect was determined by testing the significance of the group by time interaction in GEE using a one degree-of-freedom (df) test.","statisticalMethod":"Generalized Estimating Equation (GEE)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0024","value":"0.00446"},{"groupId":"OG001","spread":"0.0008","value":"0.0011"}]}],"title":"BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.001","value":"0.00265"},{"groupId":"OG001","spread":"0.0009","value":"0.00174"}]}],"title":"6m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0014","value":"0.00467"},{"groupId":"OG001","spread":"0.0034","value":"0.00742"}]}],"title":"12m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0017","value":"0.00737"},{"groupId":"OG001","spread":"0.0017","value":"0.00684"}]}],"title":"18m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.002","value":"0.01111"},{"groupId":"OG001","spread":"0.002","value":"0.01132"}]}],"title":"24m"}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"Troponin I is a biomarker for myocardial cell injury (in ng/ml). The mean is reported by arm at each timepoint with corresponding standard errors.","dispersionType":"Standard Error","groups":[{"description":"Patients received Carvedilol PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG000","title":"Arm I (Carvedilol)"},{"description":"Patients received Placebo PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG001","title":"Arm II (Placebo)"}],"paramType":"MEAN","populationDescription":"We excluded 31 participants who did not have a second time point assessment of echocardiography, resulting in 151 analyzable participants.","reportingStatus":"POSTED","timeFrame":"Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation","title":"Average Cardiac Troponin I","type":"SECONDARY","unitOfMeasure":"ng/mL"}